Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.79 |
| ▸ | NPC1 | O15118 | 3/20 | 0.73 |
| ▸ | RAB9A | P51151 | 3/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5051924 | 1.00 | EPHX2 (1.00) | EPHX2KMT2AMEN1ALDH1A1NPC1 | |
| SCHEMBL2753089 | 0.98 | EPHX2 (0.96) | EPHX2KMT2AMEN1ALDH1A1NPC1 | |
| Hydrochloric Acid SCHEMBL5047929 | 0.96 | EPHX2 (0.93) | EPHX2KMT2AMEN1ALDH1A1NPC1 | |
| SCHEMBL5049597 | 0.95 | EPHX2 (0.90) | EPHX2KMT2AMEN1ALDH1A1NPC1 | |
| SCHEMBL2469256 | 0.91 | EPHX2 (0.83) | EPHX2KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL528257 | 0.86 | EPHX2 (0.75) | EPHX2KMT2AMEN1ALDH1A1NPC1 | |
| SCHEMBL1800332 | 0.85 | EPHX2 (0.74) | EPHX2KMT2AMEN1ALDH1A1NPC1 | |
| Cadaverine Tartrate SCHEMBL5053647 | 0.85 | EPHX2 (0.74) | EPHX2KMT2AMEN1ALDH1A1NPC1 | |
| SCHEMBL13169536 | 0.85 | EPHX2 (0.83) | EPHX2KMT2AMEN1ALDH1A1NPC1 | |
| SCHEMBL3455859 | 0.85 | EPHX2 (0.83) | EPHX2KMT2AMEN1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948164-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-07-30 | — | — | EP | claimed |
| WO-2007045979-A1 | PHARMACEUTICAL COMPOSITIONS OF MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | WO | claimed |
| US-20020045548-A1 | Heat-sensitive recording sheet | SAITO CHEMICALS INSTITUTE CO., LTD. (JP) | 2002-04-18 | — | — | US | claimed |
| CN-113999131-B | Method for preparing amide derivative by amination of alkyl C-H bond under catalysis of nickel promoted by visible light | 苏州大学 | 2022-06-28 | — | — | CN | disclosed |
| CN-113999131-A | Method for preparing amide derivative by amination of alkyl C-H bond under catalysis of nickel promoted by visible light | 苏州大学 | 2022-02-01 | — | — | CN | disclosed |
| WO-2018053446-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| US-8569013-B2 | Penicillin-G acylases | CODEXIS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569013-B2 | Penicillin-G acylases | CODEXIS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8476043-B2 | Inhibitors for the soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476043-B2 | Inhibitors for the soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-02 | — | — | US | disclosed |
| US-20120270282-A1 | PENICILLIN-G ACYLASES | CODEXIS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20020045548-A1 | Heat-sensitive recording sheet | SAITO CHEMICALS INSTITUTE CO., LTD. (JP) | 2002-04-18 | — | — | US | disclosed |
| US-6245817-B1 | NEUROPEPTIDE Y | BAYER CORPORATION | 2001-06-12 | — | — | US | disclosed |
| US-6060484-A | Anti-viral method | ELI LILLY AND COMPANY (US) | 2000-05-09 | — | — | US | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| WO-1997041846-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-11-13 | — | — | WO | disclosed |
| EP-0806205-A2 | Urea, thiourea and guanidine compounds and their use as anti-viral agents | ELI LILLY AND COMPANY (US) | 1997-11-12 | — | — | EP | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| US-4508911-A | Amine intermediates for analgesic compounds | THE UPJOHN COMPANY (US) | 1985-04-02 | — | — | US | disclosed |
| US-4438130-A | Analgesic 1-oxa-, aza- and thia-spirocyclic compounds | THE UPJOHN COMPANY (US) | 1984-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270282-A1 | PENICILLIN-G ACYLASES | PGLS, PNP, NAAA | EPHX2 1859/4885KMT2A 1693/4885MEN1 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.